Immunotherapy

Immunotherapy

CHICAGO—Routine screening for hepatitis B virus (HBV) in all patients being started on immunosuppressive therapy uncovers a significant percentage with HBV surface antigen (HBsAg) and HBV core antibody (HBcAb), said Emmy Ludwig, MD, at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

As such, she recommends a universal screening program for HBV at all cancer centers. Chemotherapy and immuno suppressive drugs can cause reactivation of HBV in persons who have the virus, with morbid and potentially fatal consequences.

Page 3 of 3
Results 21 - 21 of 21